Solid Tumor: Clinical Trials

52 trials for Solid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

52 terminated. 52 Phase 2, 28 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 252Terminated 52
Phase 128Terminated 28

Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor

Trials (filtered) newest first · largest first

All 52 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
IBI3004 - Solid Tumor
Phase 1 / Phase 2TerminatedInnovent Biologics (Suzhou) Co. Ltd.52024-08-192025-12-30
Study of 23ME-01473 in Patients With Advanced Solid Malignancies
23ME-01473 - Solid Tumor
Phase 1 / Phase 2Terminated23andMe, Inc.52024-03-072024-12-04
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
REC-4881 - AXIN1 Gene Mutation, APC Gene Mutation
Phase 2TerminatedRecursion Pharmaceuticals Inc.182024-01-152026-02-23
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
OMX-0407 - Solid Tumor
Phase 1 / Phase 2TerminatediOmx Therapeutics AG682023-03-302026-07-24
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
AMXT1501, DFMO - Cancer, Solid Tumor
Phase 1 / Phase 2TerminatedAminex Therapeutics, Inc.152022-11-292024-12-24
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
Allocetra-OTS, Nivolumab, Tislelizumab - Solid Tumor, Peritoneal Metastases
Phase 1 / Phase 2TerminatedEnlivex Therapeutics RDO Ltd.142022-11-152024-04-17
Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors
GT201 - Solid Tumor
Phase 1 / Phase 2TerminatedGrit Biotechnology62022-09-142026-04-27
A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene
OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two - Hepatocellular Carcinoma, Solid Tumor
Phase 1 / Phase 2TerminatedOmega Therapeutics242022-08-192025-02-03
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
BNT142 - Solid Tumor
Phase 1 / Phase 2TerminatedBioNTech SE732022-03-222026-04-08
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Niraparib - Solid Tumor, Breast Tumor
Phase 2TerminatedTempus AI222022-03-152025-10-29
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BNT141, Nab-paclitaxel, Gemcitabine - Solid Tumor, Gastric Cancer
Phase 1 / Phase 2TerminatedBioNTech SE132022-01-182024-10-02
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Tazemetostat - Solid Tumor, ARID1A Gene Mutation
Phase 2TerminatedPrisma Health-Upstate202022-01-062026-03-17
Study of Magrolimab in Patients With Solid Tumors
Magrolimab, Docetaxel - Solid Tumor
Phase 2TerminatedGilead Sciences1062021-10-012025-05-08
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors
PRS-344/S095012 - Solid Tumor
Phase 1 / Phase 2TerminatedServier Bio-Innovation LLC462021-09-082026-06-16
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
Lerapolturev, 5% DDM - Solid Tumor, Bladder Cancer
Phase 1 / Phase 2TerminatedIstari Oncology, Inc.42021-08-012024-10-24
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Tovorafenib - Melanoma, Solid Tumor
Phase 2TerminatedDay One Biopharmaceuticals, Inc.232021-07-152025-10-02
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
AB-106 - Solid Tumor
Phase 2TerminatedNuvation Bio Inc.142021-06-012026-01-21
Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
ADG106 injection, PD-1 antibody injection - Solid Tumor, Non Hodgkin Lymphoma
Phase 1 / Phase 2TerminatedAdagene (Suzhou) Limited252021-03-112023-04-24
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
Pembrolizumab, Lenvatinib - Solid Tumor, Solid Tumor, Adult
Phase 2TerminatedMassachusetts General Hospital102021-03-082025-07-25
The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
CKD-516 plus Durvalumab - Colorectal Cancer, Solid Tumor
Phase 1 / Phase 2TerminatedTae Won Kim252021-02-242023-04-21

Showing 20 of 52. Sign in to see all of them.

Narrower conditions

Neoplasms (9)  ·  Neoplasm Metastasis (7)  ·  Colorectal Neoplasms (6)  ·  Melanoma (6)  ·  Breast Neoplasms (5)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Endometrial Neoplasms (4)  ·  Esophageal Neoplasms (4)  ·  Hematologic Neoplasms (4)  ·  Lymphoma (4)  ·  Pancreatic Neoplasms (4)  ·  Stomach Neoplasms (4)  ·  Urinary Bladder Neoplasms (4)  ·  Brain Neoplasms (3)  ·  Carcinoma, Renal Cell (3)

Broader conditions

Neoplasms by Site (27)  ·  Neoplasms (25)  ·  Neoplasms by Histologic Type (20)  ·  Neoplasms, Glandular and Epithelial (12)  ·  Skin Diseases (12)  ·  Skin and Connective Tissue Diseases (12)  ·  Carcinoma (11)  ·  Female Urogenital Diseases (11)  ·  Female Urogenital Diseases and Pregnancy Complications (11)  ·  Urogenital Diseases (11)  ·  Urogenital Neoplasms (11)  ·  Digestive System Diseases (10)  ·  Digestive System Neoplasms (10)  ·  Hemic and Lymphatic Diseases (10)  ·  Adenocarcinoma (9)

Interventions

atezolizumab (3)  ·  pembrolizumab (3)  ·  rucaparib (3)  ·  Docetaxel (2)  ·  Gemcitabine (2)  ·  Ipilimumab (2)  ·  Nivolumab (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  Bortezomib (1)  ·  CB-839 (1)  ·  CH5183284 (1)  ·  Capecitabine (1)  ·  Carboplatin (1)  ·  Cisplatin (1)  ·  DDMS (1)

Sponsors

BioNTech SE (4)  ·  CytomX Therapeutics (2)  ·  Dana-Farber Cancer Institute (2)  ·  M.D. Anderson Cancer Center (2)  ·  Pfizer (2)  ·  pharmaand GmbH (2)  ·  23andMe, Inc. (1)  ·  4D pharma plc (1)  ·  AHS Cancer Control Alberta (1)  ·  Adagene (Suzhou) Limited (1)  ·  Albert Einstein College of Medicine (1)  ·  Aminex Therapeutics, Inc. (1)  ·  Bristol-Myers Squibb (1)  ·  Calithera Biosciences, Inc (1)  ·  Columbia University (1)

Countries

United States (41)  ·  Spain (12)  ·  Australia (7)  ·  France (6)  ·  United Kingdom (6)  ·  South Korea (5)  ·  Canada (4)  ·  China (4)  ·  Netherlands (4)  ·  Belgium (3)  ·  Denmark (3)  ·  Poland (3)  ·  Singapore (3)  ·  Brazil (2)  ·  Finland (2)

Top investigators

Apostolia Tsimberidou, MD, PHD (1)  ·  Chaoyuan Kuang, MD, PhD (1)  ·  Ely Benaim, MD (1)  ·  Jaba Kokhreidze, MD (1)  ·  James Yao, MD (1)  ·  Jeffrey A. Sosman, MD (1)  ·  Jennifer Low, M.D,Ph.D (1)  ·  Ki Chung, MD (1)  ·  Kim Reiss-Binder, MD (1)  ·  Lawrence Lu, MD (1)

Results publications

PMID 25086465, PMID 29188469, PMID 31753029, PMID 31780255, PMID 31953313, PMID 34301808, PMID 34301809, PMID 34951522, PMID 35176457, PMID 37038005, PMID 37173365, PMID 37592303, PMID 37860278, PMID 38776391, PMID 40632975, PMID 42390142, PMID 42826365

NIH funding

2018 (3), 2019 (3), 2014 (1), 2015 (1), 2023 (1), P30CA012197 (1)